Treatment significantly decreased total 5hmC levels in MDS-L cells (Figure 2A, 2B), a line derived from an MDS patient [18], as well as TET2 expression levels in MDS-L cells and in human AML cell lines (Figure 2C and Supplementary Figure 1A). The gene discussed is TET2; the disease is myelodysplastic syndrome.